Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

IER5L Inhibitors

IER5L inhibitors are a class of small molecules designed to specifically target and modulate the function of the protein encoded by the immediate early response gene 5-like (IER5L). IER5L, a member of the immediate early response (IER) gene family, is associated with a range of cellular processes, including the regulation of stress responses, cell cycle control, and gene expression. The inhibition of IER5L activity through specific inhibitors allows for the modulation of its role within these cellular processes, enabling the study of its biological functions in more detail. Structurally, these inhibitors are often characterized by their capacity to interact with the IER5L protein through binding to specific active or regulatory sites, affecting its stability, function, or localization within the cell. These interactions are highly dependent on the molecular conformation of both the inhibitor and the target protein, which can lead to selective and potent inhibition of IER5L activity.

Chemically, IER5L inhibitors can vary significantly in structure, reflecting the complexity of designing molecules that can efficiently and selectively bind to their target protein. They often possess functional groups that facilitate strong binding through hydrogen bonds, hydrophobic interactions, or van der Waals forces. The chemical diversity among these inhibitors enables a range of inhibitory mechanisms, including competitive, allosteric, and covalent modification of the IER5L protein. Furthermore, the specific design of these compounds can lead to differing degrees of specificity and potency, offering tools to dissect the physiological and molecular role of IER5L. These inhibitors serve as valuable molecular probes for understanding the cellular and biochemical pathways regulated by IER5L, as well as for elucidating how this protein interacts with other signaling molecules and cellular components. Understanding these mechanisms is essential for characterizing the broader role of IER5L in various cellular contexts.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A PI3K inhibitor that can lead to reduced activation of downstream targets potentially involved in IER5L signaling pathways.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

An MEK inhibitor that can prevent ERK activation, which may be upstream or parallel to IER5L-related signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor that can disrupt MAPK pathway signaling, potentially affecting IER5L function.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, which can modulate the activity of transcription factors that may regulate IER5L expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

A PI3K inhibitor that can suppress AKT phosphorylation and may indirectly influence IER5L-mediated signaling.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor that can alter the activity of downstream proteins potentially involved in the regulation of IER5L.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

An inhibitor of MEK, which can prevent the activation of the ERK pathway, potentially impacting IER5L-associated pathways.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$102.00
$138.00
14
(1)

An AKT inhibitor that can reduce AKT-mediated signaling processes, possibly affecting IER5L-related functions.

LY3214996

1951483-29-6sc-507299
5 mg
$260.00
(0)

An ERK1/2 inhibitor that can disrupt signaling pathways that may intersect with IER5L's regulatory network.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

A CDK4/6 inhibitor that can arrest cell cycle progression, potentially affecting IER5L activity due to altered transcriptional demands during the cell cycle.